CymaBay Therapeutics Received its Third Buy in a Row


After Oppenheimer and Cantor Fitzgerald gave CymaBay Therapeutics (NASDAQ: CBAY) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Ed Arce maintained a Buy rating on CymaBay Therapeutics today and set a price target of $23. The company’s shares closed yesterday at $12.52.

According to TipRanks.com, Arce is a 5-star analyst with an average return of 27.3% and a 46.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Collegium Pharmaceutical, and Conatus Pharmaceuticals.

CymaBay Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $19.86.

See today’s analyst top recommended stocks >>

Based on CymaBay Therapeutics’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $17.01 million. In comparison, last year the company had a GAAP net loss of $5.35 million.

Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is neutral on the stock. Most recently, in March 2018, Carl Goldfischer, a Director at CBAY sold 15,000 shares for a total of $195,300.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

CymaBay Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the research and development of biopharmaceutical products. Its products include MBX-8025 and Arhalofenate, MBX-8025 aims to treat lipid and liver diseases while Arhalofenate intends to reduce gout flares and serum uric acid.

Read More on CBAY:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts